ABSTRACT: Structurally unique 6,7-seco-ent-kaurenes, which are widely distributed in the genus Isodon, have attracted considerable attention because of their antitumor activities. Previously, a convenient conversion of commercially available oridonin (1) to 6,7-seco-ent-kaurenes was developed. Herein, several novel spiro-lactone-type ent-kaurene derivatives bearing various substituents at the C-1 and C-14 positions were further designed and synthesized from the natural product oridonin. Moreover, a number of seven-membered C-ring expanded 6,7-seco-ent-kaurenes were also identified for the first time. It was observed that most of the spiro-lactone-type ent-kaurenes tested markedly inhibited the proliferation of cancer cells, with an IC50 value of as low as 0.55 μM. An investigation on its mechanism of action showed that the representative compound 7b affected the cell cycle and induced apoptosis at a low micromolar level in MCF-7 human breast cancer cells. Furthermore, compound 7b inhibited liver tumor growth in an in vivo mouse model and exhibited no observable toxic effects. Collectively, the results warrant further preclinical investigations of these spiro-lactone-type ent-kaurenes as potential novel anticancer agents.
Nature is an underexplored source of unique and desirable structural scaffolds for novel drug discovery. 1 Many natural products and their derivatives have been developed successfully for clinical applications to treat human diseases in almost all therapeutic areas. Of the 112 first-in-class drugs approved by the U.S. Food and Drug
Administration from 1999 to 2013, 31 (28%) were developed based on naturally occurring compounds. 2 The genus Isodon is well-known for producing bioactive diterpenoids with diverse carbon skeletons. [3] [4] [5] More than 700 ent-kauranoids have been identified from the genus Isodon thus far, including mainly ent-kaurenes, 6,7-seco-ent-kaurenes, and 8,9-seco-ent-kaurenes. 6 Several ent-kaurenes like oridonin (1, Scheme 1) and its analogues have been studied extensively for the development of novel anticancer agents. [7] [8] [9] [10] [11] Recently, there has been a growing interest in further investigating 6,7-seco-ent-kaurene derivatives, which may be classified into the spiro-lactone and enmein-types ( Figure 1 ), because of their broad range of bioactivities. [12] [13] [14] In particularly, spiro-lactone-type ent-kaurenes bearing diverse chemical skeletons have exhibited promising antitumor activities. 15, 16 However, for these complex 6,7-seco-ent-kaurenes, their isolation from Isodon plants in only low yields cannot meet the need for further developmental laboratory studies, while their total synthesis is also quite challenging due to the several stereogenic centers present. 17 In previous work, a convenient conversion of the commercially available oridonin (1) to 6,7-seco-ent-kaurenes was developed in high yield. [18] [19] [20] A series of spiro-lactone-type and enmein-type ent-kaurenes with diverse chemical properties and potential anticancer activities was synthesized in our laboratory. 21, 22 Among these compounds, several spiro-lactone-type derivatives have been shown to inhibit the proliferation of cancer cells, and some were found to be more potent than their parent compound, oridonin (1).
Figure 1. Structures of representative spiro-lactone and enmein-type ent-kaurenes
isolated from plants.
Based on these promising results and the ongoing interest in 6,7-seco-ent-kaurenes in the search for anticancer drug candidates with new skeletons, potent antitumor activities, and less toxic effects, 24, 25 several new spiro-lactone-type ent-kaurene derivatives bearing various substitutions at the C-1 and C-14 positions have been produced from the commercially available oridonin (1), and evaluated for their potential anticancer activities. In addition, the mechanism of action of the representative compound 7b was investigated in detail.
RESULTS AND DISCUSSION
Chemistry. Based on the previous structure-activity relationships (SARs) established, 26,27 compounds 6, 10, and 12 were designed initially by introducing preferred moieties like an alkenyl unit to enhance the resultant activity. The synthesis of the spiro-lactone-type ent-kaurenes is outlined in Schemes 1 and 2. Protection of the 7,14-dihydroxy group of oridonin (1) with 2,2-dimethoxypropane afforded compound 2 in 95% yield. The 1-hydroxy group of compound 2 was then selectively activated by MsCl, which was eliminated subsequently in the presence of Li2CO3 and
LiBr in DMF at 110 o C to provide the 1-ene 4 in 75% yield. 28 The removal of the acetonide group in the 4 with 10% HCl aqueous solution gave compound 5 in 90%
yield. The conversion of compound 5 to the spiro-lactone-type ent-kaurene 6 was achieved successfully by lead tetraacetate oxidation. Compound 6 provided a good building block to construct a library of its 14-O-derivatives (7a-k) with diverse chemical properties. As shown in Scheme 2, synthon 4 was subjected to epoxidation through m-CPBA to give intermediate 8 in 71% yield. The removal of the protecting group with 5% H2SO4 provided the desired analogue 9 bearing a C-1,2-epoxy group in 87% yield. The subsequent 6,7-ring opening reaction of compound 9 led to the generation of compound 10 in 81% yield. On the other hand, the removal of the protecting group in 3 with 10% HCl aqueous solution afforded compound 11, which was further converted to 6,7-seco-kaurene 12 using lead tetraacetate in 79% yield.
Some derivatives of compound 12 were synthesized by treatment of this substance with various acids in the presence of DMAP and EDCI. attributed to the methyl group at the C-ring, which was isomerized from an exocyclic methylene. Additionally, a deshielded singlet (δH 13.99, 1H, s) was observed, and this was attributed to a stable enol due to the presence of an adjacent lactone system. In the HMBC spectrum, a series of key correlations were observed clearly to support the However, the ring-expanded compounds 15, 16, and 18 exhibited much weaker activities against Bel-7402 cells. These results inspired us to further evaluate the detailed antiproliferative activities of spiro-lactone-type kaurenes. As shown in Table   1 , although compound 6 in bearing a C-1,2-ene group possessed better cytotoxic potencies against these four types of cancer cells than its parent, oridonin (1), the introduction of an epoxy or a mesyl group into the A-ring of these diterpenoids (10 and 12) caused a slight decrease in antiproliferative activities relative to 1. In previous studies, it was found that C-14 oxygenated derivatives of ent-kaurenes showed excellent cytotoxicities against human cancer cell lines. 29 Therefore derivatives 7a-k To investigate whether these 6,7-seco-ent-kaurenes are effective against drug-resistant cancer cells, the representative derivatives 6 and 7b were selected to test their antiproliferative activities against drug-resistant and drug-sensitive parental cells, using the MTT method. The results showed that the antiproliferative activities of these synthesized compounds were more potent for the drug-resistant cells (KB/CP4; cisplatin resistant human cervix carcinoma) than for the KB-3-1 paired drug-sensitive cells (Table S3 , Supporting Information).
Mechanism of Action Study of Compound 7b. The long-term antiproliferative
ability of compound 7b was demonstrated initially after performing a colony formation assay ( Figure S2 , Supporting Information). 31 To determine whether the suppression of cell growth by 7b is caused by a cell-cycle effect, the DNA content of the cell nuclei was detected by flow cytometry. As seen in Figure 3a , Finally, Western blotting analysis was performed to evaluate the expression of apoptosis-related proteins. 34 As shown in Figure 4 , the results revealed that incubation with compound 7b dramatically increased the relative levels of Bax, caspase 3, p-ERK, and reduced the levels of Bcl-2 and P53 expression in a concentration-dependent manner.
Taken together, these results demonstrated that 7b induced apoptosis in MCF-7 cancer cells through a mitochondria-related apoptotic pathway. Cytotoxicity Determination. The inhibitory effect of compounds on human cancer cell growth was determined using a colorimetric MTT assay. Briefly, the cell lines 
SYXK2016-0011).
Statistics. Statistical analyses were performed using Graphpad Prism (San Diego, CA, USA). The results were expressed as means ± standard deviations (SD). Student's t-test was employed to determine the statistical differences, and results were considerd statistically significant at the level of *p < 0.05, **p < 0.01, or ***p < 0.0001.
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